The IPO Buzz: Parabilis Medicines (PBLS) Prices Upsized IPO at $20 – Above Range & Stock Pops
Let’s do this again: Cancer biotech Parabilis Medicines (PBLS) upsized its IPO at pricing to 33.5 million shares – up from 33.33 million shares – and priced the deal at $20.00 - $1.00 above the top of its range – to raise $670 million on Tuesday night, June 9, 2026. It was the IPO’s second upsizing of the day. Early Tuesday morning, Parabilis Medicines (PBLS) increased its IPO..
Read more June 10, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| ERock, Inc. | EROC | 27.9 | $ 600.1 mil | 6/10/2026 Priced | S/O | S/O |
| JAB Acquisition Corp. I | JABU | 15.0 | $ 150.0 mil | 6/10/2026 Priced | S/O | S/O |
| Parabilis Medicines | PBLS | 33.5 | $ 670.0 mil | 6/10/2026 Priced | S/O | S/O |
Last 100 IPOs - June 10, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 52 |
| Number Down: | 46 |
| Number Unchanged: | 2 |
| Percentage Change From Issue Price: | 6.70% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - June 10, 2026
| Number of IPOs priced (Excluding 108 units) : | 81 |
| Number Up: | 42 |
| Number Down: | 37 |
| Number Unchanged: | 2 |
| Total Return From Issue Price: | 5.37% |
| The Nasdaq Composite Index YTD % Change | 35.22% |